Formulary Monographs [NABILONE, 9200]
|
|
NABILONE
|
|
|
|
|
|
UNCLASSIFIED THERAPEUTIC AGENTS
|
|
|
Used for the control of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic. Even though it is structurally distinct from THC, it mimics the THC pharmacological activity thro
|
|
|
The adverse effects are similar to those of cannabis. The most common are drowsiness, vertigo, and dry mouth. Neurological effects have included ataxia, confusion, disorientation, dizziness,euphoria, dysphoria, hallucinations, psychosis, depression, headache, decreased concentration, blurred vision, sleep disturbances, decreased coordination, and tremors. Use with caution in those patients who have a history of psychiatric disorders or depression, hypertension and heart disease. Patients should be warned about the use of alcohol and driving and operating machinery.
|
|
|
A dose of 1 mg - 2 mg twice daily, orally every 8-12hours. The first dose is given the evening before, or 1-3 hours before chemotherapy. Nabilone is given throughout the chemotherapy and for 24-48 hours after the last dose of chemotherapy. Not to exceed 6
|
|
|
|
|
|
|
|
|
|
|
|
|